Joaquim Bosch-Barrera

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2822856/publications.pdf

Version: 2024-02-01

78	2,838	186265	189892
papers	citations	28	50
		h-index	g-index

82	82	82	5139
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	STAT3 labels a subpopulation of reactive astrocytes required for brain metastasis. Nature Medicine, 2018, 24, 1024-1035.	30.7	285
2	Metformin: Multi-faceted protection against cancer. Oncotarget, 2011, 2, 896-917.	1.8	263
3	Metformin-induced preferential killing of breast cancer initiating CD44+CD24â^'/low cells is sufficient to overcome primary resistance to trastuzumab in HER2+ human breast cancer xenografts. Oncotarget, 2012, 3, 395-398.	1.8	134
4	Silibinin and STAT3: A natural way of targeting transcription factors for cancer therapy. Cancer Treatment Reviews, 2015, 41, 540-546.	7.7	124
5	Resveratrol targets PD-L1 glycosylation and dimerization to enhance antitumor T-cell immunity. Aging, 2020, 12, 8-34.	3.1	99
6	Chemical inhibition of acetyl-CoA carboxylase suppresses self-renewal growth of cancer stem cells. Oncotarget, 2014, 5, 8306-8316.	1.8	94
7	Targeting STAT3 with silibinin to improve cancer therapeutics. Cancer Treatment Reviews, 2017, 58, 61-69.	7.7	86
8	Metformin Is a Direct SIRT1-Activating Compound: Computational Modeling and Experimental Validation. Frontiers in Endocrinology, 2018, 9, 657.	3.5	85
9	IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations. Scientific Reports, 2013, 3, 2560.	3.3	74
10	The anti-cancer drug ABTL0812 induces ER stress-mediated cytotoxic autophagy by increasing dihydroceramide levels in cancer cells. Autophagy, 2021, 17, 1349-1366.	9.1	72
11	Silibinin suppresses EMT-driven erlotinib resistance by reversing the high miR-21/low miR-200c signature in vivo. Scientific Reports, 2013, 3, 2459.	3.3	67
12	Stem cell-like ALDH^{bright}cellular states in EGFR-mutant non-small cell lung cancer: A novel mechanism of acquired resistance to erlotinib targetable with the natural polyphenol silibinin. Cell Cycle, 2013, 12, 3390-3404.	2.6	65
13	Metformin lowers the threshold for stress-induced senescence: A role for the microRNA-200 family and miR-205. Cell Cycle, 2012, 11, 1235-1246.	2.6	56
14	BIM and mTOR expression levels predict outcome to erlotinib in EGFR-mutant non-small-cell lung cancer. Scientific Reports, 2015, 5, 17499.	3.3	55
15	Silibinin meglumine, a water-soluble form of milk thistle silymarin, is an orally active anti-cancer agent that impedes the epithelial-to-mesenchymal transition (EMT) in EGFR-mutant non-small-cell lung carcinoma cells. Food and Chemical Toxicology, 2013, 60, 360-368.	3.6	53
16	Oncometabolic mutation IDH1 R132H confers a metformin-hypersensitive phenotype. Oncotarget, 2015, 6, 12279-12296.	1.8	53
17	Silibinin is a direct inhibitor of STAT3. Food and Chemical Toxicology, 2018, 116, 161-172.	3.6	52
18	STAT3-targeted treatment with silibinin overcomes the acquired resistance to crizotinib in ALK-rearranged lung cancer. Cell Cycle, 2016, 15, 3413-3418.	2.6	49

#	Article	IF	Citations
19	Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic. Cancer Treatment Reviews, 2020, 89, 102067.	7.7	48
20	Response of brain metastasis from lung cancer patients to an oral nutraceutical product containing silibinin. Oncotarget, 2016, 7, 32006-32014.	1.8	47
21	Cross-suppression of EGFR ligands amphiregulin and epiregulin and de-repression of FGFR3 signalling contribute to cetuximab resistance in wild-type KRAS tumour cells. British Journal of Cancer, 2012, 106, 1406-1414.	6.4	42
22	Silibinin and SARS-CoV-2: Dual Targeting of Host Cytokine Storm and Virus Replication Machinery for Clinical Management of COVID-19 Patients. Journal of Clinical Medicine, 2020, 9, 1770.	2.4	42
23	Oncobiguanides: Paracelsus' law and nonconventional routes for administering diabetobiguanides for cancer treatment. Oncotarget, 2014, 5, 2344-2348.	1.8	40
24	Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. Journal of Translational Medicine, 2013, 11, 13.	4.4	38
25	The LSD1 inhibitor iadademstat (ORY-1001) targets SOX2-driven breast cancer stem cells: a potential epigenetic therapy in luminal-B and HER2-positive breast cancer subtypes. Aging, 2020, 12, 4794-4814.	3.1	38
26	Metformin rescues cell surface major histocompatibility complex class I (MHC-I) deficiency caused by oncogenic transformation. Cell Cycle, 2012, 11, 865-870.	2.6	37
27	A randomized, phase 2 evaluation of the CHK1 inhibitor, LY2603618, administered in combination with pemetrexed and cisplatin in patients with advanced nonsquamous nonâ€small cell lung cancer. Lung Cancer, 2017, 108, 212-216.	2.0	35
28	Intestinal Permeability Study of Clinically Relevant Formulations of Silibinin in Caco-2 Cell Monolayers. International Journal of Molecular Sciences, 2019, 20, 1606.	4.1	32
29	Durvalumab consolidation in patients with unresectable stage III non-small cell lung cancer with driver genomic alterations. European Journal of Cancer, 2022, 167, 142-148.	2.8	32
30	Activation of the methylation cycle in cells reprogrammed into a stem cell-like state. Oncoscience, 2016, 2, 958-967.	2.2	30
31	Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism. Nature Medicine, 2022, 28, 752-765.	30.7	30
32	Successful empirical erlotinib treatment of a mechanically ventilated patient newly diagnosed with metastatic lung adenocarcinoma. Lung Cancer, 2014, 86, 102-104.	2.0	27
33	Next-generation Sequencing for ALK and ROS1 Rearrangement Detection in Patients With Nonâ€“small-cell Lung Cancer: Implications of FISH-positive Patterns. Clinical Lung Cancer, 2019, 20, e421-e429.	2.6	27
34	The extra virgin olive oil phenolic oleacein is a dual substrate-inhibitor of catechol-O-methyltransferase. Food and Chemical Toxicology, 2019, 128, 35-45.	3.6	27
35	Extra Virgin Olive Oil Contains a Phenolic Inhibitor of the Histone Demethylase LSD1/KDM1A. Nutrients, 2019, 11, 1656.	4.1	26
36	Anti-protozoal and anti-bacterial antibiotics that inhibit protein synthesis kill cancer subtypes enriched for stem cell-like properties. Cell Cycle, 2015, 14, 3527-3532.	2.6	25

#	Article	IF	Citations
37	Toxic Epidermal Necrolysis Related to Pemetrexed and Carboplatin with Vitamin B12 and Folic Acid Supplementation for Advanced Non-Small Cell Lung Cancer. Onkologie, 2009, 32, 580-584.	0.8	24
38	Assessment of ALK Status by FISH on 1000 Spanish Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology, 2014, 9, 1816-1820.	1.1	23
39	Somatic DICER1 mutations in adult-onset pulmonary blastoma. European Respiratory Journal, 2016, 47, 1879-1882.	6.7	22
40	Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptorâ€“positive non-small cell lung cancer who might benefit from sequential tyrosine kinase inhibitor treatment. European Journal of Cancer, 2021, 149, 61-72.	2.8	21
41	Silibinin administration improves hepatic failure due to extensive liver infiltration in a breast cancer patient. Anticancer Research, 2014, 34, 4323-7.	1.1	21
42	Metformin inhibits RANKL and sensitizes cancer stem cells to denosumab. Cell Cycle, 2017, 16, 1022-1028.	2.6	19
43	A phase Ib trial of continuous once-daily oral afatinib plus sirolimus in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer and/or disease progression following prior erlotinib or gefitinib. Lung Cancer, 2017, 108, 154-160.	2.0	18
44	Tumor Cell-Intrinsic Immunometabolism and Precision Nutrition in Cancer Immunotherapy. Cancers, 2020, 12, 1757.	3.7	17
45	Direct antitumour activity of zoledronic acid: preclinical and clinical data. Clinical and Translational Oncology, 2011, 13, 148-155.	2.4	16
46	Revisiting silibinin as a novobiocin-like Hsp90â€¯C-terminal inhibitor: Computational modeling and experimental validation. Food and Chemical Toxicology, 2019, 132, 110645.	3.6	16
47	SEOM clinical guidelines for the treatment of malignant pleural mesothelioma (2020). Clinical and Translational Oncology, 2021, 23, 980-987.	2.4	16
48	Synthetic lethal interaction of cetuximab with MEK1/2 inhibition in NRAS-mutant metastatic colorectal cancer. Oncotarget, 2016, 7, 82185-82199.	1.8	16
49	Computational de-orphanization of the olive oil biophenol oleacein: Discovery of new metabolic and epigenetic targets. Food and Chemical Toxicology, 2019, 131, 110529.	3.6	15
50	An olive oil phenolic is a new chemotype of mutant isocitrate dehydrogenase 1 (IDH1) inhibitors. Carcinogenesis, 2019, 40, 27-40.	2.8	14
51	Lung Cancer Management with Silibinin: A Historical and Translational Perspective. Pharmaceuticals, 2021, 14, 559.	3.8	14
52	Zoledronic acid in lung cancer with bone metastases: a review. Expert Review of Anticancer Therapy, 2013, 13, 421-426.	2.4	13
53	BRCA1 haploinsufficiency cell-autonomously activates RANKL expression and generates denosumab-responsive breast cancer-initiating cells. Oncotarget, 2017, 8, 35019-35032.	1.8	12
54	Ethics competences in the undergraduate medical education curriculum: the Spanish experience. Croatian Medical Journal, 2016, 57, 493-503.	0.7	11

#	Article	IF	Citations
55	EphA2 receptor activation with ephrin-A1 ligand restores cetuximab efficacy in NRAS-mutant colorectal cancer cells. Oncology Reports, 2017, 38, 263-270.	2.6	11
56	Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer. Cancers, 2021, 13, 2141.	3.7	11
57	Adult onset Still's disease after first cycle of pemetrexed and gemcitabine for non-small cell lung cancer. Lung Cancer, 2009, 64, 124-126.	2.0	9
58	Primary bone lymphoma of the mandible and thyroid incidentaloma identified by 18FDG PET/CT: a case report. Cases Journal, 2009, 2, 6384.	0.4	9
59	Metabolomic mapping of cancer stem cells for reducing and exploiting tumor heterogeneity. Oncotarget, 2017, 8, 99223-99236.	1.8	9
60	Neoadjuvant Chemoradiotherapy Treatment for a Classic Biphasic Pulmonary Blastoma with High PD-L1 Expression. Anticancer Research, 2015, 35, 4871-5.	1.1	9
61	Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer. Cancers, 2021, 13, 4168.	3.7	8
62	Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer. Oncotarget, 2018, 9, 27074-27086.	1.8	8
63	Hepatic breast cancer dissemination after an iatrogenic hepatic laceration during talc pleurodesis: a case report. International Archive of Medicine, 2010, 3, 6.	1.2	6
64	The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institutionâ€™s experience. Clinical and Translational Oncology, 2012, 14, 835-841.	2.4	6
65	Transcriptional upregulation of HER2 expression in the absence of HER2 gene amplification results in cetuximab resistance that is reversed by trastuzumab treatment. Oncology Reports, 2012, 27, 1887-92.	2.6	5
66	Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data. BMC Cancer, 2021, 21, 977.	2.6	5
67	Probable drugâ€“drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer. Anti-Cancer Drugs, 2018, 29, 380-383.	1.4	4
68	The Medical Oncology resident mentor: situation and workload. Clinical and Translational Oncology, 2019, 21, 304-313.	2.4	4
69	Polycaprolactone Electrospun Scaffolds Produce an Enrichment of Lung Cancer Stem Cells in Sensitive and Resistant EGFRm Lung Adenocarcinoma. Cancers, 2021, 13, 5320.	3.7	4
70	Sensory-motor axonal peripheral neuropathy in an advanced breast cancer patient treated with ixabepilone. Clinical and Translational Oncology, 2009, 11, 765-766.	2.4	3
71	Paraneoplastic Limbic Encephalitis in a Male with Squamous Cell Carcinoma of the Lung. Journal of		

#	Article	IF	Citations
73	The practice-changing QUARTZ trial: is there any role for whole brain radiotherapy in patients with non-small cell lung cancer and brain metastases?. Translational Cancer Research, 2017, 6, S201-S204.	1.0	2
74	Mimetics of extra virgin olive oil phenols with anti-cancer stem cell activity. Aging, 2020, 12, 21057-21075.	3.1	2
75	Clinical Management of COVID-19 in Cancer Patients with the STAT3 Inhibitor Silibinin. Pharmaceuticals, 2022, 15, 19.	3.8	2
76	Bisphosphonates in Breast Cancer: From Metastasis to Prevention. Current Breast Cancer Reports, 2010, 2, 222-230.	1.0	1
77	Costs of bevacizumab and pemetrexed for advanced non-squamous NSCLC in Italy and Germany. Lung Cancer, 2011, 71, 244.	2.0	1
78	65P Fatty acid synthase (FASN) inhibition effect on EGFR TKIs sensitive and resistant cells. Journal of Thoracic Oncology, 2018, 13, S34-S35.	1.1	0